The Pharmacology of Cannabinoids in Chronic Pain

Given the biphasic nature of cannabinoid effects (where lower doses may be therapeutic while higher doses can lead to diminishing returns or adverse effects), the lack of a uniform dosing protocol presents a major confounding variable. Variability in bioavailability and metabolism can lead to inconsistent pain relief across studies, making direct comparisons difficult. It decreased mean emergency department visits in the past calendar year for patients who received marijuana as an adjunct to opioids in the treatment of non-cancer chronic pain compared to those who did not receive marijuana .

I’ve used the cream on my shoulders, but I haven’t seen any help from it either. ” 73 years (female I would choke on it for the first week), but the https://greencamp.com/safety-standards-for-thc-vaping-products/ past week I’ve been able to use it. ” 58 years (female It feels good sometimes), but I don’t like the side effects or being unable to work. ” 49 years, male Not so much with pain or mental issues. ” 56 years, female It has been absolutely fantastic as I have found the perfect mix for the right time of day. It medical cannabis takes the edge off plenty where I feel human again. ” 56 years, female

Evidence indicating moderate certainty also implies that medical cannabis use led to fewer discontinuations due to adverse events compared to opioids. The effects of cannabis for medical use and opioids when compared to a placebo were modest, with the modeled risk difference for achieving the minimal important difference in pain, sleep, and physical functioning varying from 5% to 15%. Evidence of moderate to high certainty indicated that opioids and medical cannabis likely lead to higher rates of discontinuation than a placebo, with the modeled risk difference for opioids compared to placebo at 10% (95% credible interval 8% to 12%) and for medical cannabis versus placebo at 4% (95% credible interval 1% to 7%) (see table 2, online supplemental eFigure 14–17). Evidence with moderate certainty reveals that in studies without enrichment — adverse event-related discontinuations are likely lower for medical cannabis compared to opioids (odds ratio 0.55, 95% credible interval 0.36 to 0.83) (see table 2).

Results:

Unlike opioids, it doesn’t come with the same concerns around overdose and addiction. New findings suggest it can be effective for low back pain, on par with opioids. The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday The IRB waived additional informed consent, and all procedures adhered to applicable privacy regulations.

Cannabinoids and cannabis.

All other evidence for the use of cannabinoids in headache disorders comes from case reports and clinical experience, which highlights the need for additional studies on this topic . They demonstrated a reduction in opioid doses and a reduction in maximum pain intensity (as rated on a numeric rating scale), from an mean of 8.7 to 4.9 in patient treated with THC . Conversely (Jensen et al. observed inconsistent benefits), with THC providing relief for some but not all patients, pointing to variability in individual responses. A randomized control trial by Skrabek et al. demonstrated that nabilone, a synthetic THC analog delivered in an oral formulation, significantly improved pain with an average decrease in visual analog scale pain scores of −2.04 in the nabilone group vs. placebo.

In addition to an undesired high (impaired work performance), stomach issues and ‘choking on vape’ were side effects mentioned by a few study participants. Based on the participant feedback, it was suggested that improved physical mobility may be an additional benefit experienced attributed to the reduction in pain symptoms with medical cannabis usage. Improvements in physical health and functionality were observed in the qualitative findings. These findings align well with past meta-analyses suggestive of improved pain management with medical cannabis treatment (Whiting et al. (2015; Wong et al.), 2020; Yanes et al., 2019). Overall — participants reported experimentation with different strains of medical cannabis and adjusting the CBD to THC product ratio to maximize treatment benefits. I think it makes me more tired during the day so it’s a work in progress.

In summary (studies demonstrate), with a low quality of evidence, that cannabinoids may offer an opioid-sparing effect in patients utilizing opioids to treat pain. The randomized trials analyzed in the study provided high-certainty evidence that cannabis addition had little or no effect on pain relief. A 2021 systematic review and meta-analysis by Noori et al. including eight randomized and observational studies provided very low-certainty evidence that adding cannabis reduced opioid use. One theory to explain this phenomenon is a potential substitution effect of cannabis for opioids or an opiate-sparing effect of cannabis. Multiple preclinical and animal studies have demonstrated a potential opioid-sparing effect, but a favorable translation to clinical effect has been wanted.